APO Research
Talk to an analyst

APO RESEARCH · REPORT

Somatostatin Receptor Type 2

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Somatostatin Receptor Type 2 Market Analysis and Forecast 2026-2032

19 December 2025194 pages

Choose your research edition.

Industry ResearchSomatostatin Receptor Type 2 Industry Research Report 2026113 pages · $2,950 USDIndustry Growth & TrendsGlobal Somatostatin Receptor Type 2 Industry Growth and Trends Forecast to 203287 pages · $3,450 USDMarket StructureGlobal Somatostatin Receptor Type 2 Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032180 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Somatostatin Receptor Type 2 Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Somatostatin Receptor Type 2 Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Somatostatin Receptor Type 2 market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Somatostatin Receptor Type 2 is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Somatostatin Receptor Type 2 is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Somatostatin Receptor Type 2 is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Somatostatin Receptor Type 2 is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Somatostatin Receptor Type 2 include Amryt Pharma plc, Crinetics Pharmaceuticals Inc, Daewoong Pharmaceutical Co Ltd, Ipsen SA, Progenics Pharmaceuticals Inc, Strongbridge Biopharma plc and Zucara Therapeutics Inc, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Somatostatin Receptor Type 2, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Somatostatin Receptor Type 2, also provides the revenue of main regions and countries. Of the upcoming market potential for Somatostatin Receptor Type 2, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Somatostatin Receptor Type 2 revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Somatostatin Receptor Type 2 market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Somatostatin Receptor Type 2 revenue, projected growth trends, production technology, application and end-user industry.

Somatostatin Receptor Type 2 Segment by Company

Amryt Pharma plc

Crinetics Pharmaceuticals Inc

Daewoong Pharmaceutical Co Ltd

Ipsen SA

Progenics Pharmaceuticals Inc

Strongbridge Biopharma plc

Zucara Therapeutics Inc

Somatostatin Receptor Type 2 Segment by Type

CRN-00808

PRL-2903

Lanreotide Acetate

Others

Somatostatin Receptor Type 2 Segment by Application

Oncology

Hormonal Disorder

Metabolic Disorder

Others

Somatostatin Receptor Type 2 Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Somatostatin Receptor Type 2 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Somatostatin Receptor Type 2 and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Somatostatin Receptor Type 2.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Somatostatin Receptor Type 2 in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Somatostatin Receptor Type 2 company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Somatostatin Receptor Type 2 revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Somatostatin Receptor Type 2 Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. CRN-00808 Major Player Table 3. PRL-2903 Major Player Table 4. Lanreotide Acetate Major Player Table 5. Others Major Player Table 6. Global Somatostatin Receptor Type 2 Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Oncology Major Player Table 8. Hormonal Disorder Major Player Table 9. Metabolic Disorder Major Player Table 10. Others Major Player Table 11. Somatostatin Receptor Type 2 Industry Trends Table 12. Somatostatin Receptor Type 2 Industry Drivers Table 13. Somatostatin Receptor Type 2 Industry Opportunities and Challenges Table 14. Somatostatin Receptor Type 2 Industry Restraints Table 15. Global Somatostatin Receptor Type 2 Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 16. Global Somatostatin Receptor Type 2 Market Size by Region (2021-2026) & (US$ Million) Table 17. Global Somatostatin Receptor Type 2 Market Share by Region (2021-2026) Table 18. Global Somatostatin Receptor Type 2 Market Size by Region (2027-2032) & (US$ Million) Table 19. Global Somatostatin Receptor Type 2 Market Share by Region (2027-2032) Table 20. Global Somatostatin Receptor Type 2 Revenue by Players (US$ Million) & (2021-2026) Table 21. Global Somatostatin Receptor Type 2 Revenue Market Share by Players (2021-2026) Table 22. Global Somatostatin Receptor Type 2 Key Players Ranking, 2024 VS 2025 VS 2026 Table 23. Global Somatostatin Receptor Type 2 Key Players Headquarters & Area Served Table 24. Global Somatostatin Receptor Type 2 Players, Product Type & Application Table 25. Global Somatostatin Receptor Type 2 Players Establishment Date Table 26. Global Players Market Concentration Ratio (CR5 and HHI) Table 27. Global Somatostatin Receptor Type 2 by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 28. Global Somatostatin Receptor Type 2 Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Somatostatin Receptor Type 2 Revenue by Type (2021-2026) & (US$ Million) Table 30. Global Somatostatin Receptor Type 2 Revenue by Type (2027-2032) & (US$ Million) Table 31. Global Somatostatin Receptor Type 2 Revenue Market Share by Type (2021-2026) Table 32. Global Somatostatin Receptor Type 2 Revenue Market Share by Type (2027-2032) Table 33. Global Somatostatin Receptor Type 2 Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Somatostatin Receptor Type 2 Revenue by Application (2021-2026) & (US$ Million) Table 35. Global Somatostatin Receptor Type 2 Revenue by Application (2027-2032) & (US$ Million) Table 36. Global Somatostatin Receptor Type 2 Revenue Market Share by Application (2021-2026) Table 37. Global Somatostatin Receptor Type 2 Revenue Market Share by Application (2027-2032) Table 38. Amryt Pharma plc Company Information Table 39. Amryt Pharma plc Business Overview Table 40. Amryt Pharma plc Somatostatin Receptor Type 2 Revenue and Gross Margin (US$ Million) & (2021-2026) Table 41. Amryt Pharma plc Somatostatin Receptor Type 2 Product Portfolio Table 42. Amryt Pharma plc Recent Development Table 43. Crinetics Pharmaceuticals Inc Company Information Table 44. Crinetics Pharmaceuticals Inc Business Overview Table 45. Crinetics Pharmaceuticals Inc Somatostatin Receptor Type 2 Revenue and Gross Margin (US$ Million) & (2021-2026) Table 46. Crinetics Pharmaceuticals Inc Somatostatin Receptor Type 2 Product Portfolio Table 47. Crinetics Pharmaceuticals Inc Recent Development Table 48. Daewoong Pharmaceutical Co Ltd Company Information Table 49. Daewoong Pharmaceutical Co Ltd Business Overview Table 50. Daewoong Pharmaceutical Co Ltd Somatostatin Receptor Type 2 Revenue and Gross Margin (US$ Million) & (2021-2026) Table 51. Daewoong Pharmaceutical Co Ltd Somatostatin Receptor Type 2 Product Portfolio Table 52. Daewoong Pharmaceutical Co Ltd Recent Development Table 53. Ipsen SA Company Information Table 54. Ipsen SA Business Overview Table 55. Ipsen SA Somatostatin Receptor Type 2 Revenue and Gross Margin (US$ Million) & (2021-2026) Table 56. Ipsen SA Somatostatin Receptor Type 2 Product Portfolio Table 57. Ipsen SA Recent Development Table 58. Progenics Pharmaceuticals Inc Company Information Table 59. Progenics Pharmaceuticals Inc Business Overview Table 60. Progenics Pharmaceuticals Inc Somatostatin Receptor Type 2 Revenue and Gross Margin (US$ Million) & (2021-2026) Table 61. Progenics Pharmaceuticals Inc Somatostatin Receptor Type 2 Product Portfolio Table 62. Progenics Pharmaceuticals Inc Recent Development Table 63. Strongbridge Biopharma plc Company Information Table 64. Strongbridge Biopharma plc Business Overview Table 65. Strongbridge Biopharma plc Somatostatin Receptor Type 2 Revenue and Gross Margin (US$ Million) & (2021-2026) Table 66. Strongbridge Biopharma plc Somatostatin Receptor Type 2 Product Portfolio Table 67. Strongbridge Biopharma plc Recent Development Table 68. Zucara Therapeutics Inc Company Information Table 69. Zucara Therapeutics Inc Business Overview Table 70. Zucara Therapeutics Inc Somatostatin Receptor Type 2 Revenue and Gross Margin (US$ Million) & (2021-2026) Table 71. Zucara Therapeutics Inc Somatostatin Receptor Type 2 Product Portfolio Table 72. Zucara Therapeutics Inc Recent Development Table 73. North America Somatostatin Receptor Type 2 Revenue by Type (2021-2026) & (US$ Million) Table 74. North America Somatostatin Receptor Type 2 Revenue by Type (2027-2032) & (US$ Million) Table 75. North America Somatostatin Receptor Type 2 Revenue by Application (2021-2026) & (US$ Million) Table 76. North America Somatostatin Receptor Type 2 Revenue by Application (2027-2032) & (US$ Million) Table 77. North America Somatostatin Receptor Type 2 Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 78. North America Somatostatin Receptor Type 2 Revenue by Country (2021-2026) & (US$ Million) Table 79. North America Somatostatin Receptor Type 2 Revenue by Country (US$ Million) & (2027-2032) Table 80. Europe Somatostatin Receptor Type 2 Revenue by Type (2021-2026) & (US$ Million) Table 81. Europe Somatostatin Receptor Type 2 Revenue by Type (2027-2032) & (US$ Million) Table 82. Europe Somatostatin Receptor Type 2 Revenue by Application (2021-2026) & (US$ Million) Table 83. Europe Somatostatin Receptor Type 2 Revenue by Application (2027-2032) & (US$ Million) Table 84. Europe Somatostatin Receptor Type 2 Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 85. Europe Somatostatin Receptor Type 2 Revenue by Country (2021-2026) & (US$ Million) Table 86. Europe Somatostatin Receptor Type 2 Revenue by Country (US$ Million) & (2027-2032) Table 87. China Somatostatin Receptor Type 2 Revenue by Type (2021-2026) & (US$ Million) Table 88. China Somatostatin Receptor Type 2 Revenue by Type (2027-2032) & (US$ Million) Table 89. China Somatostatin Receptor Type 2 Revenue by Application (2021-2026) & (US$ Million) Table 90. China Somatostatin Receptor Type 2 Revenue by Application (2027-2032) & (US$ Million) Table 91. Asia Somatostatin Receptor Type 2 Revenue by Type (2021-2026) & (US$ Million) Table 92. Asia Somatostatin Receptor Type 2 Revenue by Type (2027-2032) & (US$ Million) Table 93. Asia Somatostatin Receptor Type 2 Revenue by Application (2021-2026) & (US$ Million) Table 94. Asia Somatostatin Receptor Type 2 Revenue by Application (2027-2032) & (US$ Million) Table 95. Asia Somatostatin Receptor Type 2 Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 96. Asia Somatostatin Receptor Type 2 Revenue by Region (US$ Million) & (2021-2026) Table 97. Asia Somatostatin Receptor Type 2 Revenue by Region (US$ Million) & (2027-2032) Table 98. SAMEA Somatostatin Receptor Type 2 Revenue by Type (2021-2026) & (US$ Million) Table 99. SAMEA Somatostatin Receptor Type 2 Revenue by Type (2027-2032) & (US$ Million) Table 100. SAMEA Somatostatin Receptor Type 2 Revenue by Application (2021-2026) & (US$ Million) Table 101. SAMEA Somatostatin Receptor Type 2 Revenue by Application (2027-2032) & (US$ Million) Table 102. SAMEA Somatostatin Receptor Type 2 Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 103. SAMEA Somatostatin Receptor Type 2 Revenue by Country (2021-2026) & (US$ Million) Table 104. SAMEA Somatostatin Receptor Type 2 Revenue by Country (US$ Million) & (2027-2032) Table 105. Research Programs/Design for This Report Table 106. Authors List of This Report Table 107. Secondary Sources Table 108. Primary Sources List of Figures Figure 1. Somatostatin Receptor Type 2 Image Figure 2. Global Somatostatin Receptor Type 2 Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Somatostatin Receptor Type 2 Market Size Share 2021 VS 2025 VS 2032 Figure 4. CRN-00808 Image Figure 5. PRL-2903 Image Figure 6. Lanreotide Acetate Image Figure 7. Others Image Figure 8. Global Somatostatin Receptor Type 2 Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Somatostatin Receptor Type 2 Market Size Share 2021 VS 2025 VS 2032 Figure 10. Oncology Image Figure 11. Hormonal Disorder Image Figure 12. Metabolic Disorder Image Figure 13. Others Image Figure 14. Global Somatostatin Receptor Type 2 Market Size (US$ Million) & (2021-2032) Figure 15. Global Somatostatin Receptor Type 2 Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Somatostatin Receptor Type 2 Market Share by Region: 2021 VS 2025 VS 2032 Figure 17. Global Somatostatin Receptor Type 2 Players Revenue Share Top 10 and Top 5 in 2025 Figure 18. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Somatostatin Receptor Type 2 Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Somatostatin Receptor Type 2 Revenue Market Share 2021 VS 2025 VS 2032 Figure 21. Global Somatostatin Receptor Type 2 Revenue Market Share by Type (2021-2032) Figure 22. Global Somatostatin Receptor Type 2 Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Somatostatin Receptor Type 2 Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 24. Global Somatostatin Receptor Type 2 Revenue Market Share by Application (2021-2032) Figure 25. North America Somatostatin Receptor Type 2 Revenue YoY Growth (2021-2032) & (US$ Million) Figure 26. North America Somatostatin Receptor Type 2 Revenue Share by Type (2021-2032) Figure 27. North America Somatostatin Receptor Type 2 Revenue Share by Application (2021-2032) Figure 28. North America Somatostatin Receptor Type 2 Revenue Share by Country (2021-2032) Figure 29. United States Somatostatin Receptor Type 2 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Canada Somatostatin Receptor Type 2 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Mexico Somatostatin Receptor Type 2 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Europe Somatostatin Receptor Type 2 Revenue YoY Growth (2021-2032) & (US$ Million) Figure 33. Europe Somatostatin Receptor Type 2 Revenue Share by Type (2021-2032) Figure 34. Europe Somatostatin Receptor Type 2 Revenue Share by Application (2021-2032) Figure 35. Europe Somatostatin Receptor Type 2 Revenue Share by Country (2021-2032) Figure 36. Germany Somatostatin Receptor Type 2 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. France Somatostatin Receptor Type 2 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. U.K. Somatostatin Receptor Type 2 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Italy Somatostatin Receptor Type 2 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Spain Somatostatin Receptor Type 2 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Russia Somatostatin Receptor Type 2 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Netherlands Somatostatin Receptor Type 2 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Nordic Countries Somatostatin Receptor Type 2 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. China Somatostatin Receptor Type 2 Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. China Somatostatin Receptor Type 2 Revenue Share by Type (2021-2032) Figure 46. China Somatostatin Receptor Type 2 Revenue Share by Application (2021-2032) Figure 47. Asia Somatostatin Receptor Type 2 Revenue YoY Growth (2021-2032) & (US$ Million) Figure 48. Asia Somatostatin Receptor Type 2 Revenue Share by Type (2021-2032) Figure 49. Asia Somatostatin Receptor Type 2 Revenue Share by Application (2021-2032) Figure 50. Asia Somatostatin Receptor Type 2 Revenue Share by Region (2021-2032) Figure 51. Japan Somatostatin Receptor Type 2 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. South Korea Somatostatin Receptor Type 2 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. India Somatostatin Receptor Type 2 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Australia Somatostatin Receptor Type 2 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Taiwan Somatostatin Receptor Type 2 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Southeast Asia Somatostatin Receptor Type 2 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. SAMEA Somatostatin Receptor Type 2 Revenue YoY Growth (2021-2032) & (US$ Million) Figure 58. SAMEA Somatostatin Receptor Type 2 Revenue Share by Type (2021-2032) Figure 59. SAMEA Somatostatin Receptor Type 2 Revenue Share by Application (2021-2032) Figure 60. SAMEA Somatostatin Receptor Type 2 Revenue Share by Country (2021-2032) Figure 61. Brazil Somatostatin Receptor Type 2 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Argentina Somatostatin Receptor Type 2 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Chile Somatostatin Receptor Type 2 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Colombia Somatostatin Receptor Type 2 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Peru Somatostatin Receptor Type 2 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Saudi Arabia Somatostatin Receptor Type 2 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Israel Somatostatin Receptor Type 2 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. UAE Somatostatin Receptor Type 2 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Turkey Somatostatin Receptor Type 2 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Iran Somatostatin Receptor Type 2 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Egypt Somatostatin Receptor Type 2 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • CRN-00808
  • PRL-2903
  • Lanreotide Acetate
  • Others
Applications
  • Oncology
  • Hormonal Disorder
  • Metabolic Disorder
  • Others
Companies covered
  • Amryt Pharma plc
  • Crinetics Pharmaceuticals Inc
  • Daewoong Pharmaceutical Co Ltd
  • Ipsen SA
  • Progenics Pharmaceuticals Inc
  • Strongbridge Biopharma plc
  • Zucara Therapeutics Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Somatostatin Receptor Type 2 Market by Type
  3. 1.2.1 Global Somatostatin Receptor Type 2 Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 CRN-00808
  5. 1.2.3 PRL-2903
  6. 1.2.4 Lanreotide Acetate
  7. 1.2.5 Others
  8. 1.3 Somatostatin Receptor Type 2 Market by Application
  9. 1.3.1 Global Somatostatin Receptor Type 2 Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Oncology
  11. 1.3.3 Hormonal Disorder
  12. 1.3.4 Metabolic Disorder
  13. 1.3.5 Others
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 Somatostatin Receptor Type 2 Market Dynamics
  1. 2.1 Somatostatin Receptor Type 2 Industry Trends
  2. 2.2 Somatostatin Receptor Type 2 Industry Drivers
  3. 2.3 Somatostatin Receptor Type 2 Industry Opportunities and Challenges
  4. 2.4 Somatostatin Receptor Type 2 Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Somatostatin Receptor Type 2 Market Perspective (2021-2032)
  2. 3.2 Global Somatostatin Receptor Type 2 Growth Trends by Region
  3. 3.2.1 Global Somatostatin Receptor Type 2 Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Somatostatin Receptor Type 2 Market Size by Region (2021-2026)
  5. 3.2.3 Global Somatostatin Receptor Type 2 Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Somatostatin Receptor Type 2 Revenue by Players
  2. 4.1.1 Global Somatostatin Receptor Type 2 Revenue by Players (2021-2026)
  3. 4.1.2 Global Somatostatin Receptor Type 2 Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Somatostatin Receptor Type 2 Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Somatostatin Receptor Type 2 Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Somatostatin Receptor Type 2 Key Players Headquarters & Area Served
  7. 4.4 Global Somatostatin Receptor Type 2 Players, Product Type & Application
  8. 4.5 Global Somatostatin Receptor Type 2 Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Somatostatin Receptor Type 2 Market CR5 and HHI
  11. 4.6.3 2025 Somatostatin Receptor Type 2 Tier 1, Tier 2, and Tier 3
5 Somatostatin Receptor Type 2 Market Size by Type
  1. 5.1 Global Somatostatin Receptor Type 2 Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Somatostatin Receptor Type 2 Revenue by Type (2021-2032)
  3. 5.3 Global Somatostatin Receptor Type 2 Revenue Market Share by Type (2021-2032)
6 Somatostatin Receptor Type 2 Market Size by Application
  1. 6.1 Global Somatostatin Receptor Type 2 Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Somatostatin Receptor Type 2 Revenue by Application (2021-2032)
  3. 6.3 Global Somatostatin Receptor Type 2 Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Amryt Pharma plc
  2. 7.1.1 Amryt Pharma plc Company Information
  3. 7.1.2 Amryt Pharma plc Business Overview
  4. 7.1.3 Amryt Pharma plc Somatostatin Receptor Type 2 Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Amryt Pharma plc Somatostatin Receptor Type 2 Product Portfolio
  6. 7.1.5 Amryt Pharma plc Recent Developments
  7. 7.2 Crinetics Pharmaceuticals Inc
  8. 7.2.1 Crinetics Pharmaceuticals Inc Company Information
  9. 7.2.2 Crinetics Pharmaceuticals Inc Business Overview
  10. 7.2.3 Crinetics Pharmaceuticals Inc Somatostatin Receptor Type 2 Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Crinetics Pharmaceuticals Inc Somatostatin Receptor Type 2 Product Portfolio
  12. 7.2.5 Crinetics Pharmaceuticals Inc Recent Developments
  13. 7.3 Daewoong Pharmaceutical Co Ltd
  14. 7.3.1 Daewoong Pharmaceutical Co Ltd Company Information
  15. 7.3.2 Daewoong Pharmaceutical Co Ltd Business Overview
  16. 7.3.3 Daewoong Pharmaceutical Co Ltd Somatostatin Receptor Type 2 Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Daewoong Pharmaceutical Co Ltd Somatostatin Receptor Type 2 Product Portfolio
  18. 7.3.5 Daewoong Pharmaceutical Co Ltd Recent Developments
  19. 7.4 Ipsen SA
  20. 7.4.1 Ipsen SA Company Information
  21. 7.4.2 Ipsen SA Business Overview
  22. 7.4.3 Ipsen SA Somatostatin Receptor Type 2 Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Ipsen SA Somatostatin Receptor Type 2 Product Portfolio
  24. 7.4.5 Ipsen SA Recent Developments
  25. 7.5 Progenics Pharmaceuticals Inc
  26. 7.5.1 Progenics Pharmaceuticals Inc Company Information
  27. 7.5.2 Progenics Pharmaceuticals Inc Business Overview
  28. 7.5.3 Progenics Pharmaceuticals Inc Somatostatin Receptor Type 2 Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Progenics Pharmaceuticals Inc Somatostatin Receptor Type 2 Product Portfolio
  30. 7.5.5 Progenics Pharmaceuticals Inc Recent Developments
  31. 7.6 Strongbridge Biopharma plc
  32. 7.6.1 Strongbridge Biopharma plc Company Information
  33. 7.6.2 Strongbridge Biopharma plc Business Overview
  34. 7.6.3 Strongbridge Biopharma plc Somatostatin Receptor Type 2 Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Strongbridge Biopharma plc Somatostatin Receptor Type 2 Product Portfolio
  36. 7.6.5 Strongbridge Biopharma plc Recent Developments
  37. 7.7 Zucara Therapeutics Inc
  38. 7.7.1 Zucara Therapeutics Inc Company Information
  39. 7.7.2 Zucara Therapeutics Inc Business Overview
  40. 7.7.3 Zucara Therapeutics Inc Somatostatin Receptor Type 2 Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Zucara Therapeutics Inc Somatostatin Receptor Type 2 Product Portfolio
  42. 7.7.5 Zucara Therapeutics Inc Recent Developments
8 North America
  1. 8.1 North America Somatostatin Receptor Type 2 Revenue (2021-2032)
  2. 8.2 North America Somatostatin Receptor Type 2 Revenue by Type (2021-2032)
  3. 8.2.1 North America Somatostatin Receptor Type 2 Revenue by Type (2021-2026)
  4. 8.2.2 North America Somatostatin Receptor Type 2 Revenue by Type (2027-2032)
  5. 8.3 North America Somatostatin Receptor Type 2 Revenue Share by Type (2021-2032)
  6. 8.4 North America Somatostatin Receptor Type 2 Revenue by Application (2021-2032)
  7. 8.4.1 North America Somatostatin Receptor Type 2 Revenue by Application (2021-2026)
  8. 8.4.2 North America Somatostatin Receptor Type 2 Revenue by Application (2027-2032)
  9. 8.5 North America Somatostatin Receptor Type 2 Revenue Share by Application (2021-2032)
  10. 8.6 North America Somatostatin Receptor Type 2 Revenue by Country
  11. 8.6.1 North America Somatostatin Receptor Type 2 Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Somatostatin Receptor Type 2 Revenue by Country (2021-2026)
  13. 8.6.3 North America Somatostatin Receptor Type 2 Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Somatostatin Receptor Type 2 Revenue (2021-2032)
  2. 9.2 Europe Somatostatin Receptor Type 2 Revenue by Type (2021-2032)
  3. 9.2.1 Europe Somatostatin Receptor Type 2 Revenue by Type (2021-2026)
  4. 9.2.2 Europe Somatostatin Receptor Type 2 Revenue by Type (2027-2032)
  5. 9.3 Europe Somatostatin Receptor Type 2 Revenue Share by Type (2021-2032)
  6. 9.4 Europe Somatostatin Receptor Type 2 Revenue by Application (2021-2032)
  7. 9.4.1 Europe Somatostatin Receptor Type 2 Revenue by Application (2021-2026)
  8. 9.4.2 Europe Somatostatin Receptor Type 2 Revenue by Application (2027-2032)
  9. 9.5 Europe Somatostatin Receptor Type 2 Revenue Share by Application (2021-2032)
  10. 9.6 Europe Somatostatin Receptor Type 2 Revenue by Country
  11. 9.6.1 Europe Somatostatin Receptor Type 2 Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Somatostatin Receptor Type 2 Revenue by Country (2021-2026)
  13. 9.6.3 Europe Somatostatin Receptor Type 2 Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China Somatostatin Receptor Type 2 Revenue (2021-2032)
  2. 10.2 China Somatostatin Receptor Type 2 Revenue by Type (2021-2032)
  3. 10.2.1 China Somatostatin Receptor Type 2 Revenue by Type (2021-2026)
  4. 10.2.2 China Somatostatin Receptor Type 2 Revenue by Type (2027-2032)
  5. 10.3 China Somatostatin Receptor Type 2 Revenue Share by Type (2021-2032)
  6. 10.4 China Somatostatin Receptor Type 2 Revenue by Application (2021-2032)
  7. 10.4.1 China Somatostatin Receptor Type 2 Revenue by Application (2021-2026)
  8. 10.4.2 China Somatostatin Receptor Type 2 Revenue by Application (2027-2032)
  9. 10.5 China Somatostatin Receptor Type 2 Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Somatostatin Receptor Type 2 Revenue (2021-2032)
  2. 11.2 Asia Somatostatin Receptor Type 2 Revenue by Type (2021-2032)
  3. 11.2.1 Asia Somatostatin Receptor Type 2 Revenue by Type (2021-2026)
  4. 11.2.2 Asia Somatostatin Receptor Type 2 Revenue by Type (2027-2032)
  5. 11.3 Asia Somatostatin Receptor Type 2 Revenue Share by Type (2021-2032)
  6. 11.4 Asia Somatostatin Receptor Type 2 Revenue by Application (2021-2032)
  7. 11.4.1 Asia Somatostatin Receptor Type 2 Revenue by Application (2021-2026)
  8. 11.4.2 Asia Somatostatin Receptor Type 2 Revenue by Application (2027-2032)
  9. 11.5 Asia Somatostatin Receptor Type 2 Revenue Share by Application (2021-2032)
  10. 11.6 Asia Somatostatin Receptor Type 2 Revenue by Country
  11. 11.6.1 Asia Somatostatin Receptor Type 2 Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Somatostatin Receptor Type 2 Revenue by Country (2021-2026)
  13. 11.6.3 Asia Somatostatin Receptor Type 2 Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Somatostatin Receptor Type 2 Revenue (2021-2032)
  2. 12.2 SAMEA Somatostatin Receptor Type 2 Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Somatostatin Receptor Type 2 Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Somatostatin Receptor Type 2 Revenue by Type (2027-2032)
  5. 12.3 SAMEA Somatostatin Receptor Type 2 Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Somatostatin Receptor Type 2 Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Somatostatin Receptor Type 2 Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Somatostatin Receptor Type 2 Revenue by Application (2027-2032)
  9. 12.5 SAMEA Somatostatin Receptor Type 2 Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Somatostatin Receptor Type 2 Revenue by Country
  11. 12.6.1 SAMEA Somatostatin Receptor Type 2 Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Somatostatin Receptor Type 2 Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Somatostatin Receptor Type 2 Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst